Anadis fights flu
Wednesday, 20 August, 2008
Anadis [ASX: ANX] has successfully demonstrated proof-of-concept for the use of the company's antibody nasal spray as a method for fighting influenza.
The spray was shown to 'switch off' virus replication at the respiratory tract lining in animal models, reducing both the severity of flu infection and the likelihood of transmission.
Once commercialised, healthy individuals could use the spray during flu season in an effort to stave off the virus, the company said.
The company collaborated with Professor Loreena Brown from the Department of Microbiology and Immunology at the University of Melbourne on the trials.
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
